VHH Fusion Antibodies for Co-Neutralizing S. Aureus Hemolysins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Staphylococcus aureus infections are challenging due to the lack of an approved vaccine and the rise of antibiotic-resistant strains, with existing treatments failing to neutralize bacterial toxins effectively, necessitating alternative strategies that target virulence factors like alpha- and gamma-hemolysins.
Innovation Solution
Development of VHH antibodies that specifically bind and neutralize S. aureus alpha- and gamma-hemolysins, including monovalent and multivalent forms, and hetero-multimeric fusions for therapeutic, prophylactic, and diagnostic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used to treat S. aureus infections, then bacterial growth is inhibited, but antibiotic-resistant strains emerge and treatment reliability decreases
Solution Approach 1:
The patent targets bacterial toxins (harmful factors) directly rather than the bacteria themselves, converting the harm into a therapeutic opportunity by neutralizing the toxins that cause damage, thereby treating infections without selecting for antibiotic resistance
Solution Approach 2:
The patent uses antibodies as intermediary molecules that bind to and neutralize bacterial toxins, acting as a mediator between the immune system and the pathogen, allowing the body to clear infections without direct antibiotic pressure that drives resistance
2Quantity of substance
If antibiotics are used to kill bacteria, then bacterial load is reduced, but circulating toxins remain and may even be enhanced by antibiotic treatment
Solution Approach 1:
The patent provides continuous neutralization of toxins through antibody binding, ensuring that toxin activity is blocked throughout the course of infection treatment, not just during bacterial killing phases, thereby maintaining protective action continuously
Solution Approach 2:
The patent introduces antibodies as intermediary molecules that specifically bind to toxins, removing their harmful effects while allowing the bacteria to be cleared by the immune system, thereby decoupling bacterial clearance from toxin neutralization
3Adaptability or versatility
If multiple separate antibodies are used to neutralize different hemolysins, then neutralization coverage is improved, but treatment complexity increases
Solution Approach 1:
The patent merges multiple antibody specificities into a single hetero-multimeric fusion protein that contains both anti-Hla and anti-Hlg domains, thereby providing broad neutralization coverage while simplifying administration to a single therapeutic agent
Solution Approach 2:
The patent creates a universal therapeutic molecule that performs multiple functions by neutralizing different toxin types (alpha-hemolysin and gamma-hemolysin) through a single fusion protein, eliminating the need for multiple separate treatments
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The VHH antibodies demonstrate high affinity and potency in neutralizing Hlg toxins, offering potential therapeutic benefits and diagnostic capabilities, particularly against drug-resistant strains, and are stable across various production methods.
Implementation Method 1
VHH antibodies specifically binding (recognizing) an S. aureus alpha-hemolysin (Hla) or gamma-hemolysin (Hlg) component
Data Source
Figure 1
Figure 1
Figure 2
AI summary
The present invention pertains to the fields of antibody technology, medicine, pharmacology, infection biology, and medical diagnostics. More specifically, the present disclosure provides VHH antibodies that neutralize cytotoxic gamma-hemolysins of S. aureus, an approach for co-neutralizing alpha- and gamma-hemolysins by VHH-fusions, and the implementation of this approach.